Bruno
Paiva
Profesional Investigador
Marcos
González Díaz
Publicaciones en las que colabora con Marcos González Díaz (12)
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
2021
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
2017
-
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Leukemia, Vol. 31, Núm. 10, pp. 2094-2103
2016
-
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Leukemia Research, Vol. 40, pp. 1-9
-
Origin of Waldenstrom's macroglobulinaemia
Best Practice and Research: Clinical Haematology, Vol. 29, Núm. 2, pp. 136-147
2014
-
Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance
Haematologica, Vol. 99, Núm. 1, pp. 155-162
-
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Leukemia, Vol. 28, Núm. 2, pp. 391-397
-
Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction
Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773
-
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Blood, Vol. 123, Núm. 20, pp. 3073-3079
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234
-
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia
Leukemia, Vol. 27, Núm. 8, pp. 1722-1728